share_log

HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target

Benzinga ·  Aug 15 02:45  · Ratings

HC Wainwright & Co. analyst Ed Arce upgrades Cidara Therapeutics (NASDAQ:CDTX) from Neutral to Buy and announces $24 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment